Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction from a Chemical Space of Privileged Protein Binders

Development of SARS-CoV-2 entry antivirals

The global outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatened human health and public safety. The development of anti-SARS-CoV-2 therapies have been essential to curb the spread of SARS-CoV-2. Particularly, antivirals targeting viral entry have become an attractive target for the development of anti-SARS-CoV-2 therapies. In this review, we elucidate the mechanism of SARS-CoV-2 viral entry and summarize the development of antiviral inhibitors targeting viral entry. Moreover, we speculate upon future directions toward more potent inhibitors of SARS-CoV-2 entry. This study is expected to provide novel insights for the efficient discovery of promising candidate drugs against the entry of SARS-CoV-2, and contribute to the development of broad-spectrum anti-coronavirus drugs.

Direct blue 53, a biological dye, inhibits SARS-CoV-2 infection by blocking ACE2 and spike interaction in vitro and in vivo

COVID-19 is a global health problem caused by SARS-CoV-2, which has led to over 600 million infections and 6 million deaths. Developing novel antiviral drugs is of pivotal importance to slow down the epidemic swiftly. In this study, we identified five azo compounds as effective antiviral drugs to SARS-CoV-2, and mechanism study revealed their targets for impeding viral particles' ability to bind to host receptors. Direct Blue 53, which displayed the strongest inhibitory impact, inhibited five mutant strains at micromole. In vitro, mechanism study demonstrated Direct Blue 53 inhibited viral infection through interaction with the spike of SARS-CoV-2. And 25 mg/kg/d compound treatment showed 50% or 60% survival protection against lethal Delta or Omicron BA.2 infection in vivo. Taken together, our results demonstrate that azo compounds with dimethyl-biphenyl-diyl-bis(azo)bis structure may be promising anti-SARS-CoV-2 drug candidates, which provide practicable therapies with the aid of structural optimizations and further research.

Investigation of the inhibitory activity of extracts, fractions and secondary metabolites of <i>Silene</i> spp. (<i>Caryophyllaceae</i>) and <i>Serratula cupuliformis</i> (<i>Asteraceae</i>) on the replication of SARS-CoV-2 coronavirus

Aim. In vitro analysis of the inhibitory activity of extracts, fractions and secondary metabolites of plants of the genus Silene [Caryophylaceae] and Serratula cupuliformis [Asteraceae) on the replication of SARS-CoV-2.

Material and Methods. Silene spp. and Serratula cupuliformis of the Siberian Botanical Garden of National Research Tomsk State University were used. Ethanol extracts and butanol fractions of Silene spp. were prepared. The flavonoid shaftoside and the ecdysteroid 20-hydroxyecdysone from Lychnis chalcedonica were isolated. Analysis of BAS was carried out by the HPLC method. In vitro analysis of the inhibitory activity of extracts on SARS-CoV-2 replication was performed in Vero cell culture by direct inactivation [neutralization) of virions. Comparison samples were dry ethanol extracts of chaga [Inonotus obliquus, Basidiomycota), spices of cloves [Syzygium aromaticum, Myrtaceae) and root of licorice [Glycyrrhiza glabra L., Fabaceae).

Results. The inhibitory activity of ethanol extracts and butanol fractions of Silene spp., as well as individual compounds [shaftozide and 20-E) was revealed in the range of 50% effective concentrations [EC50) when dissolved in water from 339.85±83.92 pg/ml to 1.59±0.39 pg/ml and when dissolved in DMSO from 119.34±26.34 pg/ml to 2.22±0.57 pg/ml, respectively. The butanol fraction of Serratula cupuliformis was active with EC50=21.74±4.80 and 27.42±6.05 pg/mL. These results for some samples of Silene spp. and Serratula cupuliformis are comparable to the EC50 values of the comparators.

Conclusion. The results obtained suggest the presence of biologically active substances in the herbal preparations studied that act destructively on virions of SARS-CoV-2 and affect one of the main stages of its "life" cycle - on the attachment to receptors of sensitive cells.

Virtual screening and molecular dynamics simulations provide insight into repurposing drugs against SARS-CoV-2 variants Spike protein/ACE2 interface

After over two years of living with Covid-19 and hundreds of million cases worldwide there is still an unmet need to find proper treatments for the novel coronavirus, due also to the rapid mutation of its genome. In this context, a drug repositioning study has been performed, using in silico tools targeting Delta Spike protein/ACE2 interface. To this aim, it has been virtually screened a library composed by 4388 approved drugs through a deep learning-based QSAR model to identify protein-protein interactions modulators for molecular docking against Spike receptor binding domain (RBD). Binding energies of predicted complexes were calculated by Molecular Mechanics/Generalized Born Surface Area from docking and molecular dynamics simulations. Four out of the top twenty ranking compounds showed stable binding modes on Delta Spike RBD and were evaluated also for their effectiveness against Omicron. Among them an antihistaminic drug, fexofenadine, revealed very low binding energy, stable complex, and interesting interactions with Delta Spike RBD. Several antihistaminic drugs were found to exhibit direct antiviral activity against SARS-CoV-2 in vitro, and their mechanisms of action is still debated. This study not only highlights the potential of our computational methodology for a rapid screening of variant-specific drugs, but also represents a further tool for investigating properties and mechanisms of selected drugs.